How do we measure efficacy of therapy in onychomycosis: Patient, physician, and regulatory perspectives

References

• Elewski BE. Onychomycosis: pathogenesis, diagnosis, and management. Clin Microbiol Rev. 1998;11:415–29.
   PubMed Web of Science ®Google Scholar
• Milobratović D, Janković S, Vukičević J, et al. Quality of life in patients with toenail onychomycosis. Mycoses. 2013;56:543–51.
   PubMed Web of Science ®Google Scholar
• Lubeck DP, Gause D, Schein JR, et al. A health-related quality of life measure for use in patients with onychomycosis: a validation study. Qual Life Res. 1999;8:121–9.
   PubMed Web of Science ®Google Scholar
• Gupta AK, Ryder J, Summerbell RC. Comparison of efficacy criteria across onychomycosis trials: need for standardization. Int J Dermatol. 2003;42:312–15.
   PubMed Web of Science ®Google Scholar
• Albanese G, Di Cintio R, Martini C, Nicoletti A. Short therapy for tinea unguium with terbinafine: four different courses of treatment. Mycoses. 1995;38:211–14.
   PubMed Web of Science ®Google Scholar
• Alpsoy E, Yilmaz E, Basaran E. Intermittent therapy with terbinafine for dermatophyte toe-onychomycosis: a new approach. J Dermatol. 1996;23:259–62.
   PubMedGoogle Scholar
• Amichai B, Nitzan B, Mosckovitz R, Shemer A. Iontophoretic delivery of terbinafine in onychomycosis: a preliminary study. Br J Dermatol. 2010;162:46–50.
   PubMed Web of Science ®Google Scholar
• Avner S, Nir N, Baruch K, Henri T. Two novel itraconazole pulse therapies for onychomycosis: a 2-year follow-up. J Dermatolog Treat. 2006;17:117–20.
   PubMed Web of Science ®Google Scholar
• Avner S, Nir N, Henri T. Fifth toenail clinical response to systemic antifungal therapy is not a marker of successful therapy for other toenails with onychomycosis. J Eur Acad Dermatol Venereol JEADV. 2006;20:1194–6.
   PubMed Web of Science ®Google Scholar
• Avner S, Nir N, Henri T. Combination of oral terbinafine and topical ciclopirox compared to oral terbinafine for the treatment of onychomycosis. J Dermatolog Treat. 2005;16:327–30.
   PubMed Web of Science ®Google Scholar
• Baran R, Belaich S, Beylot C, et al. Comparative multicentre double-blind study of terbinafine (250 mg per day) versus griseofulvin (1 g per day) in the treatment of dermatophyte onychomycosis. J Dermatol Treat. 1997;8:93–7.
   Web of Science ®Google Scholar
• Baran R, Tosti A, Hartmane I, et al. An innovative water-soluble biopolymer improves efficacy of ciclopirox nail lacquer in the management of onychomycosis. J Eur Acad Dermatol Venereol JEADV. 2009;23:773–81.
   PubMed Web of Science ®Google Scholar
• Bräutigam M, Nolting S, Schopf RE, Weidinger G. German randomized double-blind multicentre comparison of terbinafine and itraconazole for the treatment of toenail tinea infection. Br J Dermatol. 1996;134 (Suppl:18–21). discussion 38.
   Web of Science ®Google Scholar
• Bräutigam M, Nolting S, Schopf RE, Weidinger G. Seventh Lamisil German Onychomycosis Study Group. Randomised double blind comparison of terbinafine and itraconazole for treatment of toenail tinea infection. BMJ. 1995;311:919–22.
   PubMed Web of Science ®Google Scholar
• Bräutigam M. Terbinafine versus itraconazole: a controlled clinical comparison in onychomycosis of the toenails. J Am Acad Dermatol. 1998;38:S53–6.
   PubMed Web of Science ®Google Scholar
• Buck DS, Nidorf DM, Addino JG. Comparison of two topical preparations for the treatment of onychomycosis: Melaleuca alternifolia (tea tree) oil and clotrimazole. J Fam Pract. 1994;38:601–5.
   PubMed Web of Science ®Google Scholar
• Chen J, Liao W, Wen H, et al. A comparison among four regimens of itraconazole treatment in onychomycosis. Mycoses. 1999;42:93–6.
   PubMed Web of Science ®Google Scholar
• Chen X, Hiruma M, Shiraki Y, Ogawa H. Combination therapy of once-weekly fluconazole (100, 150, or 300 mg) with topical application of ketoconazole cream in the treatment of onychomycosis. Jpn J Infect Dis. 2004;57:260–3.
   PubMed Web of Science ®Google Scholar
• De Backer M, De Keyser P, De Vroey C, Lesaffre E. A 12-week treatment for dermatophyte toe onychomycosis: terbinafine 250 mg/day vs. itraconazole 200 mg/day–a double-blind comparative trial. Br J Dermatol. 1996;134:16–17. discussion 38.
   PubMed Web of Science ®Google Scholar
• De Backer M, De Vroey C, Lesaffre E, et al. Twelve weeks of continuous oral therapy for toenail onychomycosis caused by dermatophytes: a double-blind comparative trial of terbinafine 250 mg/day versus itraconazole 200 mg/day. J Am Acad Dermatol. 1998;38:S57–63.
   PubMed Web of Science ®Google Scholar
• De Doncker P, Decroix J, Piérard GE, et al. Antifungal pulse therapy for onychomycosis. A pharmacokinetic and pharmacodynamic investigation of monthly cycles of 1-week pulse therapy with itraconazole. Arch Dermatol. 1996;132:34–41.
   PubMed Web of Science ®Google Scholar
• Degreef H, del Palacio A, Mygind S, et al. Randomized double-blind comparison of short-term itraconazole and terbinafine therapy for toenail onychomycosis. Acta Derm Venereol 1999;79:221–3.
   PubMed Web of Science ®Google Scholar
• Drake LA, Shear NH, Arlette JP, et al. Oral terbinafine in the treatment of toenail onychomycosis: North American multicenter trial. J Am Acad Dermatol. 1997;37:740–5.
   PubMed Web of Science ®Google Scholar
• Elewski B, Pollak R, Ashton S, et al. A randomized, placebo- and active-controlled, parallel-group, multicentre, investigator-blinded study of four treatment regimens of posaconazole in adults with toenail onychomycosis. Br J Dermatol. 2012;166:389–98.
   PubMed Web of Science ®Google Scholar
• Elewski BE, Aly R, Baldwin SL, et al. Efficacy and safety of tavaborole topical solution, 5%, a novel boron-based antifungal agent, for the treatment of toenail onychomycosis: results from 2 randomized phase-III studies. J Am Acad Dermatol. 2015;73:62–9.
   PubMed Web of Science ®Google Scholar
• Elewski BE, Rich P, Pollak R, et al. Efinaconazole 10% solution in the treatment of toenail onychomycosis: two phase III multicenter, randomized, double-blind studies. J Am Acad Dermatol. 2013;68:600–8.
   PubMed Web of Science ®Google Scholar
• Elewski BE, Scher RK, Aly R, et al. Double-blind, randomized comparison of itraconazole capsules vs. placebo in the treatment of toenai lonychomycosis. Cutis. 1997;59:217–20.
   PubMed Web of Science ®Google Scholar
• Emtestam L, Kaaman T, Rensfeldt K. Treatment of distal subungual onychomycosis with a topical preparation of urea, propylene glycol and lactic acid: results of a 24-week, double-blind, placebo-controlled study. Mycoses. 2012;55:532–40.
   PubMed Web of Science ®Google Scholar
• Evans EG, Sigurgeirsson B. The LION Study Group. Double blind, randomised study of continuous terbinafine compared with intermittent itraconazole in treatment of toenail onychomycosis. BMJ. 1999;318:1031–5.
   PubMed Web of Science ®Google Scholar
• Faergemann J, Anderson C, Hersle K, et al. Double-blind, parallel-group comparison of terbinafine and griseofulvin in the treatment of toenail onychomycosis. J Am Acad Dermatol. 1995;32:750–3.
   PubMed Web of Science ®Google Scholar
• Friedman-Birnbaum R, Cohen A, Shemer A, et al. Treatment of onychomycosis: a randomized, double-blind comparison study with topical bifonazole-urea ointment alone and in combination with short-duration oral griseofulvin. Int J Dermatol. 1997;36:67–9.
   PubMed Web of Science ®Google Scholar
• Ginter G, De Doncker P. An intermittent itraconazole 1-week dosing regimen for the treatment of toenail onychomycosis in dermatological practice. Mycoses. 1998;41:235–8.
   PubMed Web of Science ®Google Scholar
• Goodfield MJ, Andrew L, Evans EG. Short term treatment of dermatophyte onychomycosis with terbinafine. BMJ. 1992;304:1151.
   PubMed Web of Science ®Google Scholar
• Goodfield MJ, Rowell NR, Forster RA, et al. Treatment of dermatophyte infection of the finger- and toe-nails with terbinafine (SF 86-327, Lamisil), an orally active fungicidal agent. Br J Dermatol. 1989;121:753–7.
   PubMed Web of Science ®Google Scholar
• Goodfield MJ. Short-duration therapy with terbinafine for dermatophyte onychomycosis: a multicentre trial. Br J Dermatol. 1992;126:33–5.
   PubMed Web of Science ®Google Scholar
• Gupta AK, Konnikov N, Lynde CW. Single-blind, randomized, prospective study on terbinafine and itraconazole for treatment of dermatophyte toenail onychomycosis in the elderly. J Am Acad Dermatol. 2001;44:479–84.
   PubMed Web of Science ®Google Scholar
• Gupta AK, Leonardi C, Stoltz RR, et al. A phase I/II randomized, double-blind, placebo-controlled, dose-ranging study evaluating the efficacy, safety and pharmacokinetics of ravuconazole in the treatment of onychomycosis. J Eur Acad Dermatol Venereol JEADV. 2005;19:437–43.
   PubMed Web of Science ®Google Scholar
• Gupta AK, Lynch LE, Kogan N, Cooper EA. The use of an intermittent terbinafine regimen for the treatment of dermatophyte toenail onychomycosis. J Eur Acad Dermatol Venereol JEADV. 2009;23:256–62.
   PubMed Web of Science ®Google Scholar
• Gupta AK, Lynde CW, Konnikov N. Single-blind, randomized, prospective study of sequential itraconazole and terbinafine pulse compared with terbinafine pulse for the treatment of toenail onychomycosis. J Am Acad Dermatol. 2001;44:485–91.
   PubMed Web of Science ®Google Scholar
• Gupta AK. Ciclopirox topical solution, 8% combined with oral terbinafine to treat onychomycosis: a randomized, evaluator-blinded study. J Drugs Dermatol. 2005;4:481–5.
   PubMedGoogle Scholar
• Gupta A, Maddin S, Arlette J, et al. Itraconazole pulse therapy is effective in dermatophyte onychomycosis of the toenail: a double-blind placebo-controlled study. J Dermatol Treat. 2000;11:33–7.
   Web of Science ®Google Scholar
• Gupta AK, Fleckman P, Baran R. Ciclopirox nail lacquer topical solution 8% in the treatment of toenail onychomycosis. J Am Acad Dermatol. 2000;43:S70–80.
   PubMed Web of Science ®Google Scholar
• Haneke E, Tajerbashi M, De Doncker P, Heremans A. Itraconazole in the treatment of onychomycosis: a double-blind comparison with miconazole. Dermatology (Basel). 1998;196:323–9.
   PubMed Web of Science ®Google Scholar
• Havu V, Brandt H, Heikkilä H, et al. A double-blind, randomized study comparing itraconazole pulse therapy with continuous dosing for the treatment of toe-nail onychomycosis. Br J Dermatol. 1997;136:230–4.
   PubMed Web of Science ®Google Scholar
• Havu V, Heikkilä H, Kuokkanen K, et al. A double-blind, randomized study to compare the efficacy and safety of terbinafine (Lamisil) with fluconazole (Diflucan) in the treatment of onychomycosis. Br J Dermatol. 2000;142:97–102.
   PubMed Web of Science ®Google Scholar
• Hofmann H, Bräutigam M, Weidinger G, Zaun H. LAGOS II Study Group. Treatment of toenail onychomycosis. A randomized, double-blind study with terbinafine and griseofulvin. LAGOS II study group. Arch Dermatol. 1995;131:919–22.
   PubMedGoogle Scholar
• Honeyman J. Itraconazole versus terbinafine (LAMISIL®): which is better for the treatment of onychomycosis? J Eur Acad Dermatol Venereol. 1997;9:215–21.
   Web of Science ®Google Scholar
• Jones HE, Zaias N. Double-blind, randomized comparison of itraconazole capsules and placebo in onychomycosis of toenail. Int J Dermatol. 1996;35:589–90.
   PubMed Web of Science ®Google Scholar
• Lauharanta J. Comparative efficacy and safety of amorolfine nail lacquer 2% versus 5% once weekly. Clin Exp Dermatol. 1992;17:41–3.
   PubMed Web of Science ®Google Scholar
• Lebwohl MG, Daniel CR, Leyden J, et al. Efficacy and safety of terbinafine for nondermatophyte and mixed nondermatophyte and dermatophyte toenail onychomycosis. Int J Dermatol. 2001;40:358–60.
   PubMed Web of Science ®Google Scholar
• Ling MR, Swinyer LJ, Jarratt MT, et al. Once-weekly fluconazole (450 mg) for 4, 6, or 9 months of treatment for distal subungual onychomycosis of the toenail. J Am Acad Dermatol. 1998;38:S95–102.
   PubMed Web of Science ®Google Scholar
• Maddin S, Quiring J, Bulger L. Randomized, placebo-controlled, phase 3 study of itraconazole for the treatment of onychomycosis. J Drugs Dermatol. 2013;12:758–63.
   PubMed Web of Science ®Google Scholar
• Malay DS, Yi S, Borowsky P, et al. Efficacy of debridement alone versus debridement combined with topical antifungal nail lacquer for the treatment of pedal onychomycosis: a randomized, controlled trial. J. Foot Ankle Surg (Off Publ Am Coll Foot Ankle Surg). 2009;48:294–308.
   PubMed Web of Science ®Google Scholar
• Menéndez S, Falcón L, Maqueira Y. Therapeutic efficacy of topical OLEOZON® in patients suffering from onychomycosis. Mycoses. 2011;54:e272–7.
   Google Scholar
• Montana JB, Scher RK. A double-blind, vehicle-controlled study of the safety and efficacy of fungoid tincture in patients with distal subungual onychomycosis of the toes. Cutis Cutan Med Pract. 1994;53:313–16.
   PubMed Web of Science ®Google Scholar
• Odom R, Daniel CR, Aly R. A double-blind, randomized comparison of itraconazole capsules and placebo in the treatment of onychomycosis of the toenail. J Am Acad Dermatol. 1996;35:110–11.
   PubMed Web of Science ®Google Scholar
• Piepponen T, Blomqvist K, Brandt H, et al. Efficacy and safety of itraconazole in the long-term treatment of onychomycosis. J Antimicrob Chemother. 1992;29:195–205.
   PubMed Web of Science ®Google Scholar
• Romero-Cerecero O, Zamilpa A, Jiménez-Ferrer J, et al. Double-blind clinical trial for evaluating the effectiveness and tolerability of Ageratina pichinchensis extract on patients with mild to moderate onychomycosis. A comparative study with ciclopirox. Planta Med. 2008;74:1430–5.
   PubMed Web of Science ®Google Scholar
• Sanmano B, Hiruma M, Mizoguchi M, Ogawa H. Combination therapy consisting of week pulses of oral terbinafine plus topical application of terbinafine cream in the treatment of onychomycosis. J Dermatolog Treat. 2004;15:245–51.
   PubMedGoogle Scholar
• Schalka S, Nunes S, Gomes Neto A. Comparative clinical evaluation of efficacy and safety of a formulation containing ciclopirox 8% in the form of a therapeutic nail lacquer in two different posologies for the treatment of onychomycosis of the toes. An Bras Dermatol. 2012;87:19–25.
   PubMedGoogle Scholar
• Scher RK, Breneman D, Rich P, et al. Once-weekly fluconazole (150, 300, or 450 mg) in the treatment of distal subungual onychomycosis of the toenail. J Am Acad Dermatol. 1998;38:S77–86.
   PubMed Web of Science ®Google Scholar
• Sigurgeirsson B, Billstein S, Rantanen T, et al. L.I.ON. Study: efficacy and tolerability of continuous terbinafine (Lamisil) compared to intermittent itraconazole in the treatment of toenail onychomycosis. Lamisil vs. itraconazole in onychomycosis. Br J Dermatol. 1999;141:5–14.
   PubMed Web of Science ®Google Scholar
• Sigurgeirsson B, Elewski BE, Rich PA, et al. Intermittent versus continuous terbinafine in the treatment of toenail onychomycosis: a randomized, double-blind comparison. J Dermatolog Treat. 2006;17:38–44.
   PubMed Web of Science ®Google Scholar
• Sigurgeirsson B, van Rossem K, Malahias S, Raterink K. A phase II, randomized, double-blind, placebo-controlled, parallel group, dose-ranging study to investigate the efficacy and safety of 4 dose regimens of oral albaconazole in patients with distal subungual onychomycosis. J Am Acad Dermatol. 2013;69:416–25.
   PubMed Web of Science ®Google Scholar
• Svejgaard EL, Brandrup F, Kragballe K, et al. Oral terbinafine in toenail dermatophytosis. A double-blind, placebo-controlled multicenter study with 12 months' follow-up. Acta Derm Venereol. 1997;77:66–9.
   PubMed Web of Science ®Google Scholar
• Syed TA, Qureshi ZA, Ali SM, et al. Treatment of toenail onychomycosis with 2% butenafine and 5% Melaleuca alternifolia (tea tree) oil in cream. Trop Med Int Health. 1999;4:284–7.
   PubMed Web of Science ®Google Scholar
• Takahata Y, Hiruma M, Shiraki Y, et al. Treatment of dermatophyte onychomycosis with three pulses of terbinafine (500 mg day for a week). Mycoses. 2009;52:72–6.
   PubMed Web of Science ®Google Scholar
• Tausch I, Bräutigam M, Weidinger G, Jones TC. Evaluation of 6 weeks treatment of terbinafine in tinea unguium in a double-blind trial comparing 6 and 12 weeks therapy. The Lagos V Study Group. Br J Dermatol. 1997;136:737–42.
   PubMed Web of Science ®Google Scholar
• Tschen EH, Bucko AD, Oizumi N, et al. Efinaconazole solution in the treatment of toenail onychomycosis: a phase 2, multicenter, randomized, double-blind study. J Drugs Dermatol. 2013;12:186–92.
   PubMed Web of Science ®Google Scholar
• van der Schroeff JG, Cirkel PK, Crijns MB, et al. A randomized treatment duration-finding study of terbinafine in onychomycosis. Br J Dermatol. 1992;126:36–9.
   PubMed Web of Science ®Google Scholar
• Warshaw EM, Fett DD, Bloomfield HE, et al. Pulse versus continuous terbinafine for onychomycosis: a randomized, double-blind, controlled trial. J Am Acad Dermatol. 2005;53:578–84.
   PubMed Web of Science ®Google Scholar
• Watson A, Marley J, Ellis D, Williams T. Terbinafine in onychomycosis of the toenail: a novel treatment protocol. J Am Acad Dermatol. 1995;33:775–9.
   PubMed Web of Science ®Google Scholar
• Yadav P, Singal A, Pandhi D, Das S. Comparative efficacy of continuous and pulse dose terbinafine regimes in toenail dermatophytosis: a randomized double-blind trial. Indian J Dermatol Venereol Leprol. 2015;81:363–9.
   PubMed Web of Science ®Google Scholar
• Rehder P, Nguyen TT. A new concept in the topical treatment of onychomycosis with cyanoacrylate, undecylenic acid, and hydroquinone. Foot Ankle Spec. 2008;1:93–6.
   PubMedGoogle Scholar
• Warrick D, Church L. Continuous terbinafine versus intermittent itraconazole for toenail onychomycosis. J Fam Pract. 1999;48:492–3.
   PubMedGoogle Scholar
• Ghannoum M, Isham N, Catalano V. A second look at efficacy criteria for onychomycosis: clinical and mycological cure. Br J Dermatol. 2014;170:182–7.
   PubMed Web of Science ®Google Scholar
• Shemer A, Sakka N, Baran R, et al. Clinical comparison and complete cure rates of Terbinafine efficacy in affected onychomycotic toenails. J Eur Acad Dermatol Venereol JEADV. 2015;29:521–6.
   PubMed Web of Science ®Google Scholar
• Shemer A, Gupta AK, Farhi R, et al. When is onychomycosis onychomycosis? A cross-sectional study of fungi in normal-appearing nails. Br J Dermatol. 2015;172:380–3.
   PubMed Web of Science ®Google Scholar
• Gupta AK, Konnikov N, MacDonald P, et al. Prevalence and epidemiology of toenail onychomycosis in diabetic subjects: a multicentre survey. Br J Dermatol. 1998;139:665–71.
   PubMed Web of Science ®Google Scholar
• Gupta AK, Lynde CW, Jain HC, et al. A higher prevalence of onychomycosis in psoriatics compared with non-psoriatics: a multicentre study. Br J Dermatol. 1997;136:786–9.
   PubMed Web of Science ®Google Scholar
• Lipner S, Scher RK. Onychomycosis: current and future therapies. Cutis. 2014;93:60–3.
   PubMed Web of Science ®Google Scholar
• Gupta A, Cooper E. Comparison of visual assessments versus planimetry assessments in a large-scale clinical trial of onychomycosis. J Dermatol Treat. 2014;25:256–9.
   PubMed Web of Science ®Google Scholar
• Valeant Pharmaceuticals. JUBLIA® (efinaconazole) topical solution, 10% [Internet]. Available from: http://www.accessdata.fda.gov/drugsatfda_docs/label/2014/203567s000lbl.pdf. Accessed September 17, 2014.
   Google Scholar
• Kerydin. Package Insert: Kerydin (tavaborole) topical solution, 5% [Internet]. Available from: www.accessdata.fda.gov/drugsatfda_docs/label/2014/204427s000lbl.pdf. Accessed December 18, 2015.
   Google Scholar
• Aventis Pharmaceuticals Inc. PENLAC nail lacquer topical solution 8% package insert. 2004.
   Google Scholar
• Lamisil. Package Insert: LAMISIL (terbinafine hydrochloride) Tablets, 250 mg Drugs@FDA: FDA Approved Drug Products 2012 [Internet]. Available from: www. accessdata.fda.gov/drugsatfda_docs/label/2012/020539s021lbl.pdf.
   Google Scholar
• Sporanox. Package insert: SPORANOX! (itraconazole) Capsules. Drugs@FDA: FDA approved drug products 2012 [Internet]. Available from: www.accessdata.fda.gov/drugsatfda_docs/label/2012/020083s048s049s050lbl.pdf.
   Google Scholar
• Rodriguez DA. Efinaconazole topical solution, 10%, for the treatment of mild and moderate toenail onychomycosis. J Clin Aesthet Dermatol. 2015;8:24–9.
   PubMedGoogle Scholar
• Gupta AK, De Doncker P, Scher RK, et al. Itraconazole for the treatment of onychomycosis. Int J Dermatol. 1998;37:303–8.
   PubMed Web of Science ®Google Scholar
• Scher RK, Tavakkol A, Sigurgeirsson B, et al. Onychomycosis: diagnosis and definition of cure. J Am Acad Dermatol. 2007;56:939–44.
   PubMed Web of Science ®Google Scholar
• Werschler WP, Bondar G, Armstrong D. Assessing treatment outcomes in toenail onychomycosis clinical trials. Am J Clin Dermatol. 2004;5:145–52.
   PubMed Web of Science ®Google Scholar
• De Cuyper C, Hindryckx PH. Long-term outcomes in the treatment of toenail onychomycosis. Br J Dermatol. 1999;141 (Suppl):15–20.
   Web of Science ®Google Scholar